HC Wainwright Reaffirms “Buy” Rating for Coya Therapeutics (NASDAQ:COYA)

Coya Therapeutics (NASDAQ:COYA)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research note issued on Monday,Benzinga reports. They presently have a $18.00 price objective on the stock. HC Wainwright’s price objective points to a potential upside of 270.37% from the stock’s current price.

COYA has been the subject of a number of other reports. Lake Street Capital reissued a “buy” rating and set a $17.00 price objective on shares of Coya Therapeutics in a research report on Wednesday, November 5th. Wall Street Zen upgraded shares of Coya Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. BTIG Research increased their price objective on shares of Coya Therapeutics from $15.00 to $16.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. Chardan Capital reaffirmed a “buy” rating and set a $14.00 price objective on shares of Coya Therapeutics in a research report on Thursday, January 8th. Finally, D. Boral Capital reiterated a “buy” rating and set a $15.00 target price on shares of Coya Therapeutics in a research note on Wednesday, January 21st. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Coya Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $16.00.

Coya Therapeutics Trading Up 2.5%

Coya Therapeutics stock opened at $4.86 on Monday. The firm has a market capitalization of $101.67 million, a P/E ratio of -4.38 and a beta of 0.27. Coya Therapeutics has a twelve month low of $3.94 and a twelve month high of $8.29. The stock’s fifty day simple moving average is $5.36 and its 200-day simple moving average is $5.88.

Coya Therapeutics (NASDAQ:COYA) last released its earnings results on Wednesday, November 12th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.12). Coya Therapeutics had a negative return on equity of 55.76% and a negative net margin of 462.24%.The company had revenue of $3.56 million for the quarter, compared to analyst estimates of $3.70 million. Sell-side analysts predict that Coya Therapeutics will post -1.15 earnings per share for the current year.

Hedge Funds Weigh In On Coya Therapeutics

Several large investors have recently bought and sold shares of COYA. JPMorgan Chase & Co. purchased a new position in shares of Coya Therapeutics during the third quarter worth about $28,000. Lantern Wealth Advisors LLC acquired a new stake in shares of Coya Therapeutics in the 3rd quarter valued at about $66,000. Oppenheimer & Co. Inc. purchased a new position in Coya Therapeutics during the 4th quarter worth approximately $81,000. Northwestern Mutual Wealth Management Co. acquired a new position in Coya Therapeutics during the second quarter worth approximately $119,000. Finally, Prosperity Wealth Management Inc. lifted its stake in Coya Therapeutics by 16.4% in the third quarter. Prosperity Wealth Management Inc. now owns 23,800 shares of the company’s stock valued at $136,000 after buying an additional 3,350 shares during the last quarter. Institutional investors and hedge funds own 39.75% of the company’s stock.

About Coya Therapeutics

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.